FDA announces guidance for industry titled Changes to Disposable Manufacturing Materials: Questions and Answers

July 29, 2022

Disposable material turbine inhaler

Today, FDA is announcing the availability of a level 2 guidance for industry titled, Changes to Disposable Manufacturing Materials: Questions and Answers. FDA receives questions about the limited availability of disposable manufacturing materials during periods of increased demand (e.g., public health emergencies or natural disasters). Limited availability of disposable manufacturing materials can affect sterile drugs and biological products. This guidance describes chemistry, manufacturing, and controls (CMC) post-approval changes related to disposable manufacturing materials that applicants can pursue in drug and biological product manufacturing. Applicants should use science-based and risk-based principles, and current FDA guidances for industry, to determine the appropriate reporting category to communicate changes to disposable manufacturing materials.

This guidance applies to biologics license application (BLA) products; human drug products marketed as new drug applications (NDAs) or abbreviated new drug applications (ANDAs); and animal drugs marketed as new animal drug applications (NADAs) or abbreviated new animal drug applications (ANADAs). This guidance also applies to all manufacturing establishments, including those that perform functions under contract as defined in the guidance for industry Contract Manufacturing Arrangements for Drugs: Quality Agreements.

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.



July 3, 2018

FDA Approves First Marijuana-Derived Drug for the Treatment of Epilepsy

On Monday, June 25th, FDA approved GW Pharmaceuticals’ Epidiolex (cannabidiol) for the treatment of two rare and severe forms of epilepsy. Epidiolex is the first FDA-approved drug that contains a...

July 8, 2016

Federal Circuit Court Requires Biosimilar Makers Participate in “Patent Dance” & Give 180-Day Notice

On Tuesday, July 5th the Federal Circuit Court announced the final decision in the case of Amgen v. Apotex, ruling that manufacturers of biosimilar products must notify their brand-name competitors...

January 10, 2014

Unapproved Codeine Products and Some DESI Drugs need FDA Approval or Cease Marketing

In a Federal Register notice published today, the Food and Drug Administration (FDA) announced its intention to take enforcement action against misbranded or unapproved prescription products...